GIGABYTE
24.6.2021 12:47:12 CEST | Business Wire | Press release
GIGABYTE, a world leader in computer technology, is excited to be part of MWC (Mobile World Congress) to present its products and insights on Edge computing , and be joined by innovators and decision-makers who will shape the future of 5G deployments and 6G planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005477/en/
GIGABYTE presents a series of servers that are “short and sweet”, and available in either x86 or Arm platforms to support diverse applications. Not only are these Edge servers shortened to depths ranging from only 400-600mm to fit in more environments for telecom deployments, but also ready to serve as HPCs to handle challenging workloads for AI and data processing that are closer to users’ applications.
- E152-ZE0 - Supports 3rd Gen AMD EPYC 7003 and 7002 processors, is extremely short with 400mm in depth, comes with 8 DIMM slots, and supports two U.2 NVMe SSDs. The E152 chamber for dual-slot GPUs can also be used for two single-slot cards operating at Gen4 x16, and two low-profile expansion slots on the front to provide user with powerful performance and flexibility for implementation.
- E162-220 - Designed for 3rd Gen Intel Xeon Scalable processors and has 16 DIMMs for industry standard 8-channel memory, and supports two U.2 SSDs and three M.2 connectors onboard with Gen4 PCIe transmission. All I/Os are designed in the same direction, making it suitable not only for installation in data centers, but also for deployment in base stations to provide 5G MEC or edge computing for services.
- E251-U70 - The first GIGABYTE edge server designed for 2nd Gen Intel Xeon Scalable processors, supporting six 2.5” SATA/SAS bays on the front-left, and a dual-slot GPU plus a FHFL single-slot card on the front-right. Notably, this server was chosen by NVIDIA Aerial Developer Kit for development and deployment of vRAN stack. E251-U71, a SKU variant that is NEBS design ready, is designed for extreme conditions such as high temperature, humidity or altitude.
- E252-P30 – Built for workloads on Arm architecture and uses Ampere Altra processors with up to 80 cores and 16 DIMMS for a wealth of possibilities in the cloud, the server is a viable option when considering TCO. It has six SSDs bays and lots of expansion slots for low-profile accelerators, storage, or networking.
The “short”ness of GIGABYTE Edge servers’ chassis and the “sweet”ness of its performance capabilities will prove to be indispensable equity in telecommunications, as the success in 5G deployments demands a widespread of MEC networks that are both closely-and-intelligently-connected.
GIGABYTE is an engineer, visionary, and leader in the tech world that uses its hardware expertise, patented innovations, and industry leadership to create, inspire, and advance. With over 30 years of celebrated experience, GIGABYTE is pleased to be the backbone of the IT infrastructure and provide the industry with data center expertise and cutting-edge server products that can accelerate scientific and technological breakthroughs.
https://www.mwcbarcelona.com/exhibitors/gigabyte-technology
See more presentations: https://www.gigabyte.com/Tech-Tune-In
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005477/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom